Effects of aldosterone on coronary function

Pharmacological Reports

Volumn 61, Issue 1, 2009, Pages 58-66

  Benard, Ludovic ^a   Milliez, Paul ^a   Ambroisine, Marie Lory ^a   Messaoudi, Smail ^a   Samuel, Jane Lise ^a   Delcayre, Claude ^a  

^a APHP   (France)

Author keywords

Aldosterone; Angiotensin; Cardiac fibrosis; Coronary function; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; HORMONE RECEPTOR; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; POTASSIUM CHANNEL; SPIRONOLACTONE; VALSARTAN;

CONFERENCE PAPER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TARGET CELL;

EID: 66949166631     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70007-6     Document Type: Conference Paper

References (49)

1. Adler GK, Williams GH: Aldosterone: villain or protector? Hypertension, 2007, 50, 31-32.
2. Ambroisine ML, Favre J, Oliviero P, Rodriguez C, Gao J, Thuillez C, Samuel JL et al.: Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation, 2007, 116, 2435-2443.
3. Bassett MH, White PC, Rainey WE: The regulation of aldosterone synthase expression. Mol Cell Endocrinol, 2004, 217, 67-74.
4. Bauersachs J, Widder JD: Endothelial dysfunction in heart failure. Pharmacol Rep, 2008, 60, 119-126.
5. + current density in rat ventricular myocytes. J Physiol, 2001, 537, 151-160.
6. Bois P, Selye H: 2-Methyl-9α-chlorocortisol, a new synthetic mineralocorticoid with unusually intense nephrotoxic actions. Can Med Assoc J, 1956, 75, 720-724.
7. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernández B, Ballesteros S, Fernández-Tresguerres J, Lahera V: Aldosterone and the vascular system. J Steroid Biochem Mol Biol, 2008, 109, 331-335.
8. De Mello WC, Gerena Y: Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. Regul Pept, 2008, 151, 54-60.
9. Delcayre C, Swynghedauw B: Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol, 2002, 34, 1577-1584.
10. Dworakowski R, Alom-Ruiz SP, Shah AM: NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep, 2008, 60, 21-28.
11. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 2000, 101, 594-597.
12. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, Bauersachs J: Immediate mineralo-corticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension, 2008, 51, 905-914.
13. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J et al.: Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation, 2004, 110, 1819-1825.
14. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, Postlethwaite AE, Weber KT: Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol, 2003, 285, H813-821.
15. Gomez-Sanchez CE, Gomez-Sanchez EP: Editorial: Cardiac steroidogenesis - new sites of synthesis, or much ado about nothing? J Clin Endocrinol Metab, 2001, 86, 5118-5120.
16. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP: Aldosterone biosynthesis in the rat brain. Endocrinology, 1997, 138, 3369-3373.
17. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M: Human mineralo-corticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol, 2005, 19, 1697-1710.
18. Gwóźdź P, Drelicharz L, Kozlovski VI, Chlopicki S: Prostacyclin, but not nitric oxide, is the major mediator of acetylcholine-induced vasodilatation in the isolated mouse heart. Pharmacol Rep, 2007, 59, 545-552.
19. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y et al.: Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation, 2001, 104, 137-139.
20. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem, 1994, 269, 24316-24320.
21. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension, 2008, 51, 734-741.
22. Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralo-cortocoid receptors in human coronary artery smooth muscle cells. Circ Res, 2005, 96, 643-650.
23. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S, Yoshikawa T: Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation, 2005, 111, 2157-2164.
24. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation, 2004, 109, 2213-2220.
25. Krug AW, Ehrhart-Bornstein M: Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension, 2008, 51, 1252-1258.
26. Lemarie CA, Paradis P, Schiffrin EL: New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med, 2008, 86, 673-678.
27. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R et al.: Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation, 2004, 109, 2792-2800.
28. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS: Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation, 2004, 109, 1933-1937.
29. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P et al.: Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J, 2005, 26, 2193-2199.
30. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 2005, 45, 1243-1248.
31. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M: Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res, 2005, 97, 434-442.
32. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E et al.: Aldosterone production is activated in failing ventricle in humans. Circulation, 2001, 103, 72-77.
33. Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M, Gollasch M et al.: Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension, 2008, 51, 1372-1378.
34. Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL: Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol, 2005, 83, 999-1006.
35. Ouvrard-Pascaud A, Puttini S, Sainte-Marie Y, Athman R, Fontaine V, Cluzeaud F et al.: Conditional gene expression in renal collecting duct epithelial cells: use of the inducible Cre-lox system. Am J Physiol Renal Physiol, 2004, 286, F180-187.
36. Pitt B, Ahmed A, Love TE, Krum H, Nicolau J, Cardoso JS, Parkhomenko A et al.: History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension, 2008, 52, 271-278.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003, 348, 1309-1321.
38. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341, 709-717.
39. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C: Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension, 1999, 33, 981-986.
40. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol, 2002, 283, H1802-H1810.
41. Shimoni Y, Chen K, Emmett T, Kargacin G: Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. Br J Pharmacol, 2008, 154, 675-687.
42. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation, 1999, 99, 2694-2701.
43. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem, 1998, 273, 4883-4891.
44. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol, 2002, 161, 1773-1781.
45. Tait SA, Tait JF, Coghlan JP: The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol, 2004, 217, 1-21.
46. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G et al.: Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation, 2004, 109, 1284-1291.
47. van den Meiracker AH, Batenburg WW: Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart. J Hypertens, 2008, 26, 1307-1309.
48. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension, 2002, 40, 504-510.
49. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 2000, 102, 2700-2706.